Infographics - Middle East And Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market

Two therapies are used for treatment of ITP in Middle East, and it is categorized into first-line therapy (Corticosteroids, intravenous immunoglobulin (IVIG), and anti-D immune globulin) and second-line therapy (thrombopoietin receptor agonists, monoclonal antibody). However, despite availability of these therapies, some patients still remain refractory to the treatment.

The ongoing research for treatment of ITP is focused on combining therapies and addressing multiple mechanisms of the disease simultaneously. As per data published by the American Society of Hematology in July 2018, the emerging combination therapies for ITP treatment are the combination of drugs, dexamethasone and rituximab which has been examined in several trials and has been indicated to provide superior results to either drug as monotherapy in some patients, and the possibility to revert lymphocyte subset abnormalities commonly seen in active disease. The addition of cyclosporine to rituximab and dexamethasone has also been evaluated in small adult studies and has provided enduring remission in a subset of treated patients, without substantial reported toxicity.

Market Dynamics

Increasing prevalence of immune thrombocytopenic purpura in pediatric population is expected to drive growth of the immune thrombocytopenic purpura drugs market in Middle East and Turkey. For instance, according to data published by the Paediatric Blood Cancer journal in 2013, around 10% of children with acute immune thrombocytopenia purpura were admitted to hospitals in Egypt in 2013.

The immune thrombocytopenic purpura drugs market growth in the Middle East and Turkey is expected to be hampered, owing to slower execution of rules and regulations regarding the approval and launch of treatment drugs compared to North America and Europe. For instance, in the Middle East, Amgen Inc.'s Nplate (romiplostim) is the only drug currently available for treatment of immune (idiopathic) thrombocytopenic purpura (ITP). This drug is present in the U.S. since 2003. Later in 2006, Amgen launched it in Israel, Kuwait, Egypt, and Lebanon.

Key features of the study:

This report provides in-depth analysis of the Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, country outlook, and competitive strategies adopted by leading players
It profiles key players in the Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Amgen Inc., Octapharma AG, Novartis AG, Swedish Orphan Biovitrum AB, and Rigel Pharmaceuticals, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Drug Type:
- Steroid
- Immunoglobulins
- Thrombopoietin Receptor Agonist
- Others
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Country:
- Turkey
  - By Drug Type:
    - Steroid
    - Immunoglobulins
    - Thrombopoietin Receptor Agonist
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Israel
  - By Drug Type:
    - Steroid
    - Immunoglobulins
    - Thrombopoietin Receptor Agonist
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Egypt
  - By Drug Type:
    - Steroid
    - Immunoglobulins
    - Thrombopoietin Receptor Agonist
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Saudi Arabia
  - By Drug Type:
    - Steroid
    - Immunoglobulins
    - Thrombopoietin Receptor Agonist
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- UAE
  - By Drug Type:
    - Steroid
    - Immunoglobulins
    - Thrombopoietin Receptor Agonist
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Rest of Middle East
  - By Drug Type:
    - Steroid
    - Immunoglobulins
    - Thrombopoietin Receptor Agonist
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
Company Profiles
- Amgen Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Octapharma AG
- Novartis AG
- Swedish Orphan Biovitrum AB
- Rigel Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
Market Overview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Drug Type
  - Market Snippet, By Distribution Channel
  - Market Snippet, By Country
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Market Trends
- Regulatory Landscape
- Reimbursement Scenario
- PEST Analysis
- Epidemiology Analysis
- Diagnosis Rate/Ratio
- Patient and Physician Perspective About the Existing Treatment
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Drug Type, 2019 – 2027, (US$ Million)
- Introduction
  - Market Share Analysis, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Steroid
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Immunoglobulins
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Thrombopoietin Receptor Agonist
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Million)
- Introduction
  - Market Share Analysis, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Country, 2019 – 2027, (US$ Million)
- Introduction
  - Market Share Analysis, By Country, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, By Country, 2017 – 2027
  - Country Trends
- Turkey
  - Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Israel
  - Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Egypt
  - Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Saudi Arabia
  - Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- UAE
  - Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Rest of Middle East
  - Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Competitive Landscape
- Company Profiles
  - Amgen Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Octapharma AG
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Novartis AG
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Swedish Orphan Biovitrum AB
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Rigel pharmaceuticals, Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
- Analyst Views
Section
- References
- Research Methodology
- About Us and Sales Contact

*Browse 20 market data tables and 21 figures on " Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market” - Global forecast to 2027”

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now